CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Diseased Saphenous Vein Grafts
Six-Month Angiographic, Intravascular Ultrasound, and Clinical Follow-Up of the RRISC Trial
Paul Vermeersch, MD*,1,*,
Pierfrancesco Agostoni, MD*,1,
Stefan Verheye, MD, PhD*,
Paul Van den Heuvel, MD*,
Carl Convens, MD*,
Nico Bruining, PhD ,
Frank Van den Branden, MD* and
Glenn Van Langenhove, MD, PhD*
* Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium
Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands.
Manuscript received May 3, 2006;
revised manuscript received July 17, 2006,
accepted July 18, 2006.
* Reprint requests and correspondence: Dr. Paul Vermeersch, Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Lindendreef 1, 2020 Antwerp, Belgium. (Email: paul.vermeersch{at}zna.be).
OBJECTIVES: We sought to compare, in a randomized fashion, sirolimus-eluting stents (SES) versus bare-metal stents (BMS) in saphenous vein grafts (SVGs).
BACKGROUND: Sirolimus-eluting stents reduce restenosis and repeated revascularization in native coronary arteries compared with BMS. However, randomized data in SVG are absent.
METHODS: Patients with SVG lesions were randomized to SES or BMS. All were scheduled to undergo 6-month coronary angiography. The primary end point was 6-month angiographic in-stent late lumen loss. Secondary end points included binary angiographic restenosis, neointimal volume by intravascular ultrasound and major adverse clinical events (death, myocardial infarction, target lesion, and vessel revascularization).
RESULTS: A total of 75 patients with 96 lesions localized in 80 diseased SVGs were included: 38 patients received 60 SES for 47 lesions, whereas 37 patients received 54 BMS for 49 lesions. In-stent late loss was significantly reduced in SES (0.38 ± 0.51 mm vs. 0.79 ± 0.66 mm in BMS, p = 0.001). Binary in-stent and in-segment restenosis were reduced, 11.3% versus 30.6% (relative risk [RR] 0.37; 95% confidence interval [CI] 0.15 to 0.97, p = 0.024) and 13.6% versus 32.6% (RR 0.42; 95% CI 0.18 to 0.97, p = 0.031), respectively. Median neointimal volume was 1 mm3 (interquartile range 0 to 13) in SES versus 24 (interquartile range 8 to 34) in BMS (p < 0.001). Target lesion and vessel revascularization rates were significantly reduced, 5.3% versus 21.6% (RR 0.24; 95% CI 0.05 to 1.0, p = 0.047) and 5.3% versus 27% (RR 0.19; 95% CI 0.05 to 0.83, p = 0.012), respectively. Death and myocardial infarction rates were not different.
CONCLUSIONS: Sirolimus-eluting stents significantly reduce late loss in SVG as opposed to BMS. This is associated with a reduction in restenosis rate and repeated target lesion and vessel revascularization procedures. (The RRISC Study; http://clinicaltrials.gov/ct/show; NCT00263263
[ClinicalTrials.gov]
).
|
Abbreviations and Acronyms
| | BMS = bare-metal stent | | CI = confidence interval | | IVUS = intravascular ultrasound | | MACE = major adverse cardiac event | | MI = myocardial infarction | | MLD = minimal luminal diameter | | PCI = percutaneous coronary intervention | | RR = relative risk | | RVD = reference vessel diameter | | SES = sirolimus-eluting stent | | SVG = saphenous vein graft | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2006 48: A47-A48.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. T. Ko, H. Guo, H. C. Wijeysundera, M. I. Zia, V. Dzavik, M. W. A. Chu, S. E. Fremes, E. A. Cohen, and J. V. Tu
Long-Term Safety and Effectiveness of Drug-Eluting Stents for the Treatment of Saphenous Vein Grafts Disease: A Population-Based Study
J. Am. Coll. Cardiol. Intv.,
September 1, 2011;
4(9):
965 - 973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lee, S.-J. Park, D. E. Kandzari, A. J. Kirtane, W. F. Fearon, E. S. Brilakis, P. Vermeersch, Y.-H. Kim, R. Waksman, J. Mehilli, et al.
Saphenous Vein Graft Intervention
J. Am. Coll. Cardiol. Intv.,
August 1, 2011;
4(8):
831 - 843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Ziada, A. Abdel-Latif, and M. E. Wiisanen
Reply
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
591 - 593.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Rozenman
Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Interventions
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
590 - 591.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Brilakis, C. Lichtenwalter, A.-r. R. Abdel-karim, J. A. de Lemos, O. Obel, T. Addo, M. Roesle, D. Haagen, B. V. Rangan, B. Saeed, et al.
Continued Benefit From Paclitaxel-Eluting Compared With Bare-Metal Stent Implantation in Saphenous Vein Graft Lesions During Long-Term Follow-Up of the SOS (Stenting of Saphenous Vein Grafts) Trial
J. Am. Coll. Cardiol. Intv.,
February 1, 2011;
4(2):
176 - 182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Wiisanen, A. Abdel-Latif, D. Mukherjee, and K. M. Ziada
Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Interventions: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol. Intv.,
December 1, 2010;
3(12):
1262 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-M. Paradis, P. Belisle, L. Joseph, O. F. Bertrand, R. DeLarochelliere, J.-P. Dery, E. Larose, J. Rodes-Cabau, and S. Rinfret
Drug-Eluting or Bare Metal Stents for the Treatment of Saphenous Vein Graft Disease: A Bayesian Meta-Analysis
Circ Cardiovasc Interv,
December 1, 2010;
3(6):
565 - 576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Brilakis, T. Y. Wang, S. V. Rao, S. Banerjee, S. Goldman, K. Shunk, B. Kar, D. R. Holmes Jr, D. Dai, C. T. Chin, et al.
Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: A Report From the American College of Cardiology National Cardiovascular Data CathPCI Registry
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
1068 - 1073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Stolker, K. F. Kennedy, J. B. Lindsey, S. P. Marso, M. J. Pencina, D. E. Cutlip, L. Mauri, N. S. Kleiman, D. J. Cohen, and on behalf of the EVENT Investigators
Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry
Circ Cardiovasc Interv,
August 1, 2010;
3(4):
327 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Brilakis, J. M. Lasala, D. A. Cox, P. B. Berger, T. S. Bowman, R. M. Starzyk, and K. D. Dawkins
Outcomes After Implantation of the TAXUS Paclitaxel-Eluting Stent in Saphenous Vein Graft Lesions: Results From the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) Program
J. Am. Coll. Cardiol. Intv.,
July 1, 2010;
3(7):
742 - 750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Latib, L. Ferri, A. Ielasi, J. Cosgrave, C. Godino, E. Bonizzoni, E. Romagnoli, A. Chieffo, M. Valgimigli, C. Penzo, et al.
Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts
Circ Cardiovasc Interv,
June 1, 2010;
3(3):
249 - 256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Brodie, H. Wilson, T. Stuckey, M. Nussbaum, S. Laurent, B. Bradshaw, A. Humphrey, C. Metzger, J. Hermiller, F. Krainin, et al.
Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1105 - 1112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Douglas Jr
Are Our Patients Better Off With Drug-Eluting Stents in Saphenous Vein Grafts?
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1113 - 1115.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lichtenwalter, J. A. de Lemos, M. Roesle, O. Obel, E. M. Holper, D. Haagen, B. Saeed, J. M. Iturbe, K. Shunk, J. K. Bissett, et al.
Clinical Presentation and Angiographic Characteristics of Saphenous Vein Graft Failure After Stenting: Insights From the SOS (Stenting Of Saphenous Vein Grafts) Trial
J. Am. Coll. Cardiol. Intv.,
September 1, 2009;
2(9):
855 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Bittl
Drug-Eluting Stents for Saphenous Vein Graft Lesions: The Limits of Evidence
J. Am. Coll. Cardiol.,
March 17, 2009;
53(11):
929 - 930.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Brilakis, C. Lichtenwalter, J. A. de Lemos, M. Roesle, O. Obel, D. Haagen, B. Saeed, C. Gadiparthi, J. K. Bissett, R. Sachdeva, et al.
A Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions: The SOS (Stenting Of Saphenous Vein Grafts) Trial
J. Am. Coll. Cardiol.,
March 17, 2009;
53(11):
919 - 928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Grines
Off-Label Use of Drug-Eluting Stents: Putting it in Perspective
J. Am. Coll. Cardiol.,
February 12, 2008;
51(6):
615 - 617.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Abbott, M. R. Voss, M. Nakamura, H. A. Cohen, F. Selzer, K. E. Kip, H. A. Vlachos, R. L. Wilensky, and D. O. Williams
Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood Institute Dynamic Registry
J. Am. Coll. Cardiol.,
November 20, 2007;
50(21):
2029 - 2036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and A. Chieffo
Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease)
Circulation,
September 18, 2007;
116(12):
1424 - 1432.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part II: Unsettled Issues
Circulation,
August 21, 2007;
116(8):
961 - 968.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Agostoni, P. Vermeersch, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, and G. Van Langenhove
Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J.,
August 1, 2007;
28(15):
1912 - 1913.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, G. Van Langenhove, and DELAYED RRISC (Death and Events at Long-term follo
Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts: Results From the Randomized DELAYED RRISC Trial
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
261 - 267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis
"Crying Fire in a Theater" or a "Confirmatory Sighting?"
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
268 - 269.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jaffe and B. H. Strauss
Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Abbate, G. G.L. Biondi-Zoccai, P. Agostoni, M. J. Lipinski, and G. W. Vetrovec
Recurrent angina after coronary revascularization: a clinical challenge
Eur. Heart J.,
May 1, 2007;
28(9):
1057 - 1065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Sirolimus-Eluting vs. Bare-Metal Stents for SVG lesions
Journal Watch Cardiology,
January 10, 2007;
2007(110):
2 - 2.
[Full Text]
|
|
|
|
